HighVista Strategies added 96,218 shares of Tyra Biosciences, now valued at $3.11 million, as the stock outperformed the S&P 500 by 250 percentage points.
HighVista Strategies increased its position in Tyra Biosciences (NASDAQ:TYRA) by 96,218 shares, valued at $3.11 million, according to an SEC filing dated May 15, 2026. The transaction was based on the quarterly average closing price, with the position’s value rising by $4.11 million by quarter-end due to share appreciation and new purchases.
Tyra Biosciences shares closed at $36.51 on May 14, 2026, up 280% over the past year, outperforming the S&P 500 by 250 percentage points. The stock now represents 1.39% of HighVista’s 13F assets under management, ranking outside its top five holdings.
HighVista’s top holdings include DBC ($30.61 million), ABVX ($12.61 million), PRAX ($8.48 million), COGT ($7.58 million), and SYRE ($7.38 million). Tyra Biosciences focuses on targeted cancer and rare disease therapies, with a lead candidate in clinical development.